Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. by Dowsett, M. et al.
Br. J. Cancer (1985), 52, 31-35
Effective inhibition by low dose aminoglutethimide of
peripheral aromatization in postmenopausal breast cancer
patients
M. Dowsett1, S.J. Santner2, R.J. Santen2, S.L. Jeffcoatel & I.E. Smith3
'Department ofBiochemical Endocrinology, Chelsea Hospitalfor Women, Dovehouse Street, London SW3
6LT, UK; 2Department ofMedicine, Division ofEndocrinology, Milton S. Hershey Medical Center,
Pennsylvania State University College ofMedicine, Hershey, Pennsylvania 17033, USA and 3Medical Breast
Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for
postmenopausal breast cancer in low dosage (250mgday-1). The mechanism of action of this approach is
thought to be the inhibition of peripheral aromatase, the enzyme which converts androstenedione to oestrone.
The activity of this enzyme was measured in vivo by injection with 3H-androstenedione and 14C-oestrone and
found to be 0.20% +0.05 in 5 patients on low dose AG therapy. In comparison with previously published
data this demonstrates a 92% inhibition of peripheral aromatase activity confirming aromatase inhibition as a
viable aim in the endocrine treatment of breast cancer.
Aminoglutethimide (AG) is a clinically effective
endocrine treatment for advanced postmenopausal
breast cancer (Lipton et al., 1974; Smith et al.,
1978; Santen et al., 1981; Harris et al., 1982), in
which it has been used almost exclusively in doses
of 750-1000mgday-1, in combination with hydro-
cortisone (HC). This therapeutic regime was derived
with the aim of suppressing adrenal androgen
synthesis (Lipton et al., 1974; Wells et al., 1978)
which was expected to result from previously
reported inhibition by AG of the conversion of
cholesterol to pregnenolone by 20,22-desmolase
(Cohen, 1967; Dexter et al., 1967). HC was added to
the regime to prevent a rise in adrenocorticotrophic
hormone, which would result from suppression of
cortisol synthesis, and which might overcome the
enzyme block (Wells et al., 1978).
More recently it has become apparent that
AG+HC has little effect on serum levels of adrenal
androgens (Samojlik et al., 1980; Harris et al.,
1983) and its clinical effectiveness in breast cancer
is probably due to inhibition by AG of peripheral
(Santen et al., 1978) and perhaps intratumoural
aromatization of androgens to oestrogens (Abul-
HaiJ, 1980; Miller et al., 1982; Tilson-Mallet et al.,
1984). The inhibitory potency of AG on aromatase
in vitro has been shown to be at least ten-fold
greater than on the 20,22 desmolase (Graves &
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Salhanick, 1979) and this has led to the
examination of the clinical and endocrine
effectiveness of AG at low dosage (250mgday-1)
without HC (Harris et al., 1983; Stuart-Harris et
al., 1984, 1985). When used in a dose of 1000mg
(+40mgHG)day-1, AG was found to inhibit
peripheral aromatase activity in vivo by at least
95% (Santen et al. 1978). We report here the
measurement of this activity in vivo in
postmenopausal breast cancer patients undergoing
treatment at a lower dosage (250mgday 1).
Patients and methods
Radioactive injections
Five patients treated with AG 125mg twice daily
were studied. These patients were part of a clinical
study of the effectiveness of this treatment (Stuart-
Harris et al., 1984) and their clinical details are
given in Table I. Approval from the local ethical
committee, informed consent and a DHSS licence
were obtained before commencement of the study.
Each patient received by bolus intravenous injection
120pCi of [7a-3H] androstenedione (A4A,
30Cimmol-, New England Nuclear) and 1pCi of
[4-14C] oestrone (E1, 55mCimmol-1, Amersham
International) in 58ml isotonic saline between 10.30
and 12.00. One ml of this mixture was retained for
estimation of 3H:14C ratio. All urine passed during
the next 72h was collected and was kept at -20°C
until analysis.
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Table I Patient details at time of study
Time since
Time on AG primary
Age Weight treatment diagnosis Previous
Patient (years) (kg) (months) (years) chemotherapy Sites ofdisease Response
1 58 78 14 8 Chest wall Stable
2 70 70 14 9 Pleura Partial
3 69 56 19 24 Pleura Partial
4 76 54 17 4 (i) Tamoxifen Skin/lymph nodes Complete
(ii) Cyclophosphamide
5 70 73 11 1 Skin, bone Partial
Response assessed according to standard UICC criteria.
Purification ofurinary oestrone
The initial stages of purification (i.e. Amberlite
chromatography, f-glucuronidase digestion, ethyl
acetate extraction and phenolic extraction) were as
previously described (Santen et al., 1978). After
nearly drying the residues from the phenolic
extract, they were subjected to thin layer chromato-
graphy (TLC) as outlined in Table II. The first
system listed was used twice in 4 of the 5 samples;
its function was to remove enough extraneous
material so that the samples would not smear in
subsequent TLCs. The final system was preceded by
an acetylation, performed by adding 12 drops of
pyridine and 6 drops of acetic anhydride to the
sample apd incubating overnight at room
temperature.
Table II Solvent systems used in the thin-layer
chromatography steps in the purification of oestrone
System no. System composition
I Benzene:Ethanol (80:20)
II Methylene chloride:Ether (90:10)
III Methylene chloride:Methanol (95:5)
IV Chloroform:Ethyl acetate (80:20)
V Methylene chloride:Ether (96:4)
Calculation ofA4A to E1 rho values
3H: 14C ratio of E1 was determined after each
chromatographic purification step. 14C c.p.m. were
corrected for background and 3H c.p.m. for spill-
over from 14C which was 14.7% in these studies.
The conversion of A4A to E1 (p) was calculated
according to the formula %(p) =3H: 14C ratio
urinary E1 3H: 14C ratio injection mixture x 100.
The 3H: 14C ratio after the final purification step
was used in each case.
Results
The 3H:14C ratio of the injection mixture and of
urinary E1 at each stage of purification are shown
in Table III together with the calculated p values.
The 3H: 14C ratio of urinary E1 was essentially
constant between the last 2 chromatographic steps.
The mean value for the conversion of A4A to E
was 0.20+0.56% (s.d.).
It was not possible to determine pretreatment
values in these patients but for comparative
purposes values may be drawn from previously
published studies (Poortman et al., 1973;
MacDonald et al., 1978; Santen et al., 1978) which
used the same methodology. These data are shown
in Table IV, and are plotted in Figure 1 together
with the p values from patients in the current study,
and 2 patients treated with 1000mg AG from a
previous study (Santen et al., 1978). A mean p
value of 2.5%+0.8 (s.d.) may be derived from the
pooled data. Comparison (unpaired t-test) of these
values with those obtained in the 5 patients treated
with low dose AG shows that the latter group of
values were significantly lower (P<0.001, t=6.77)
showing a mean 92% inhibition of conversion of
A4A to E1. Comparison of the values in the 5
treated.patients against the 2 obtained previously in
patients treated with 1000mg AG daily (p=0.01,
0.08) showed these 2 values to be significantly
lower (P<0.05, t=2.64).
Discussion
Aromatase inhibition would appear to be an
effective mechanism for the endocrine treatment of
postmenopausal breast cancer. This has been
previously suggested by demonstration of clinical
responses to testololactone (Goldenberg et al.,
1973) and aminoglutethimide (Santen et al., 1981)
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Table IV % conversion A4A to El measured in the
urine of untreated postmenopausal women.
% conversion % conversion
Patient A4A to E1 Patient A4A to E
Group Ia Group 2b
1 2.1 1 1.6
2 1.3 2 1.5
3 3.8 3 2.4
4 2.8 4 3.3
5 3.3 5d 2.4
6 1.9 6 2.4
7 3.0 7 2.7
8 1.6 8 3.8
9d 2.8 9 2.1
lod 3.7
Ild 2.4 Group 3C
12d 3.0 Id 1.9
13d 2.9 2d 1.1
14d 2.8
15d 2.6
aPoortman et al. (1973), weight range 41-71 kg;
bMacDonald et al. (1978), excluding patients with
ovarian serous cystadenocarcinomas, weight range 46-
73kg;
'Santen et al. (1978), weight range 45-63 kg;
dBreast cancer patients.
c
*2
0
0
0
0Q0
4
3
No treatment Treatment
Figure 1 % conversion of A4A to E1 in
postmenopausal females. Left-hand column-no
treatment: (-) normals, (0) breast cancer patients,
(O) breast cancer patients before 1000mgAGday- 1.
Right-hand column-breast cancer patients on AG:
(O) 1000mgday-1, (®) 250mgday -1.
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response to 4-hydroxy-androstenedione, the suicide
inhibitor ofaromatase (Coombes et al., 1984).
AG is a clinically effective agent in post-
menopausal breast cancer patients when used
without HC at the lower than usual dose of 125mg
twice daily (Stuart-Harris et al., 1984). Serum levels
of oestrone and oestradiol are significantly
suppressed by that dose whilst there are significant
increases in the serum levels of androstenedione
and testosterone (Harris et al., 1983; Stuart-Harris
et al., 1984, 1985). We have therefore suggested
that AG acts through inhibition of peripheral
aromatase in this circumstance, and in the current
study we have been able to confirm that low dose
AG is indeed an effective inhibitor of aromatization
in vivo.
Comparison of the current data with those from
previously published reports is not ideal, but seems
acceptable firstly because of the internal consistency
of the present data and secondly since the
previously published 2 results (Santen et al., 1978;
Group 3, Table IV) which were obtained from
untreated breast cancer patients in the Hershey
Laboratory were comparable with those in the
other two reports. In addition, there was a close
similarity in the techniques used to derive
conversion rates between all 3 reports and the
current study.
Peripheral aromatization is known to be directly
related to patient weight (MacDonald et al., 1978).
The mean weight of the 5 patients studied was
66kg, which is in the upper part of the weight
range of the patients in the studies cited (see
Legend Table IV). The pretreatment rho values in
the 5 patients may therefore have been a little
higher than that of the groups used for comparison.
It would appear that the current low dose
treatment may be a little less effective in aromatase
inhibition than 1000mg AG although the
comparison is on very small numbers and the
statistics are of low power. It is probable that the
degree of difference is of little clinical significance,
but it should be noted that this dose of AG alone
also results in a doubling of serum androstenedione
levels (Stuart-Harris et al., 1985). The combined
effect of less complete aromatase inhibition and
higher substrate concentration may make this
treatment less effective than conventional dose
AG+HC in the suppression of oestrogen synthesis.
We are currently comparing the effects of low dose
AG with and without HC on oestrogen
suppression.
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